Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.

Abstract:

:Estrogen receptor beta (ERbeta) is widely expressed in mammary epithelium. ERbeta expression is reported to decline during carcinogenesis of the breast and other tissues. In this study, we examined the consequences of a loss of ERbeta expression in mammary epithelial cells. We knocked down ERbeta transcript levels in human mammary epithelial MCF-10A cells and in MCF-7 breast cancer cells by means of stable transfection with a specific shRNA plasmid. ERbeta knockdown resulted in a significant growth increase of both cell types in a ligand-independent manner. This effect was accompanied by elevated cyclin A2 expression in MCF-10A cells and by decreased expression of growth-inhibitory p21/WAF and epithelial cell marker cytokeratine 8 in both cell lines. Transfection of ERbeta shRNA did not alter the absent proliferative estrogen response of MCF-10A cells, but conferred sensitivity to selective estrogen receptor modulator tamoxifen to this cell line. In contrast, ERbeta knockdown diminished estrogen responsiveness of MCF-7 breast cancer cells and also weakened the effect of tamoxifen on this cell line. These ligand-dependent effects only observed in MCF-7 cells exhibiting a high ERalpha/beta ratio were accompanied by smaller estrogenic repression of p21/WAF expression, an impaired tamoxifen-triggered induction of this gene and by relative downregulation of ERalpha and cyclin A2 transcript levels. Our data suggest that ERbeta exerts antiproliferative effects both on MCF-10A and MCF-7 cells in a ligand- and ERalpha-independent manner by regulation of p21/WAF or cyclin A2 gene expression. Knockdown of ERbeta in both cell types was sufficient to significantly decrease transcript levels of epithelial cell marker cytokeratin 8. The results of this study support the hypothesis that ERbeta acts as a tumor suppressor in mammary epithelium.

authors

Treeck O,Lattrich C,Springwald A,Ortmann O

doi

10.1007/s10549-009-0413-2

subject

Has Abstract

pub_date

2010-04-01 00:00:00

pages

557-65

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

120

pub_type

杂志文章
  • Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

    abstract::Ductal carcinoma in situ (intraductal carcinoma) of the breast is a commonly recognized and curable clinical entity. Patients with intraductal carcinoma are at risk to develop invasive breast cancer presumably due to a transition from the noninvasive to the invasive phase of growth. Primary breast malignancies commonl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00689717

    authors: Iglehart JD,Kerns BJ,Huper G,Marks JR

    更新日期:1995-06-01 00:00:00

  • Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.

    abstract::Oestrogen receptor (ER) negative breast cancers are more likely to achieve a pathological complete response (pCR) to neoadjuvant chemotherapy compared to those with ER positive tumours. ER positive tumours exhibit low proliferation and ER negative cancers high proliferation. The aim of this study was to determine to w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0329-x

    authors: Jones RL,Salter J,A'Hern R,Nerurkar A,Parton M,Reis-Filho JS,Smith IE,Dowsett M

    更新日期:2010-01-01 00:00:00

  • Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial.

    abstract::Results from several randomised mammography screening trials have shown that it is possible to reduce mortality in breast cancer by mammographic screening at least for women above 50 years of age. The purpose of this article is to present data on mortality in breast cancer in study and control groups of the Stockholm ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1005872617944

    authors: Frisell J,Lidbrink E,Hellström L,Rutqvist LE

    更新日期:1997-09-01 00:00:00

  • Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.

    abstract::Beta-blockers (BB) drugs have been used for decades worldwide, mainly to treat hypertension. However, in recent epidemiological studies, BBs were suggested to improve cancer prognosis. In the wake of this evidence, we evaluated the possible therapeutic effect of BBs in triple-negative breast cancer (TNBC) patients. We...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2654-3

    authors: Botteri E,Munzone E,Rotmensz N,Cipolla C,De Giorgi V,Santillo B,Zanelotti A,Adamoli L,Colleoni M,Viale G,Goldhirsch A,Gandini S

    更新日期:2013-08-01 00:00:00

  • Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.

    abstract:PURPOSE:Clinical trials demonstrated adjuvant aromatase inhibitor treatment is superior for decreasing breast cancer recurrence risk over adjuvant tamoxifen treatment as early as 2001. Yet clinical use for adjuvant treatment was not recommended by the American Society of Clinical Oncology until 2004. Aromatase inhibito...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9558-z

    authors: Aiello EJ,Buist DS,Wagner EH,Tuzzio L,Greene SM,Lamerato LE,Field TS,Herrinton LJ,Haque R,Hart G,Bischoff KJ,Geiger AM

    更新日期:2008-02-01 00:00:00

  • Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

    abstract:PURPOSE:To investigate and compare the effects of mobile health (mHealth) and pedometer with conventional exercise program using a brochure on physical function and quality of life (QOL). METHODS:The study was a prospective, quasi-randomized multicenter trial where 356 patients whose cancer treatment had been terminat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-016-4065-8

    authors: Uhm KE,Yoo JS,Chung SH,Lee JD,Lee I,Kim JI,Lee SK,Nam SJ,Park YH,Lee JY,Hwang JH

    更新日期:2017-02-01 00:00:00

  • Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from hngh-risk patients.

    abstract::We describe a method for the isolation of free DNA from ductal lavage (DL) and nipple aspirate fluid (NAF), and its evaluation for the presence of LOH at the BRCA1 and FHIT genes and for mitochondrial DNA (mtDNA) mutations at the D310 marker, to improve early detection of breast cancer. We evaluated 26 DL and six NAF ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000018406.03679.2e

    authors: Isaacs C,Cavalli LR,Cohen Y,Pennanen M,Shankar LK,Freedman M,Singh B,Liu M,Gallagher A,Rone JD,Dickson RB,Sidransky D,Haddad BR

    更新日期:2004-03-01 00:00:00

  • Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.

    abstract::Targeting HER-2 over-expressing breast cancer cells with trastuzumab has resulted in significant improvements in both disease-free and overall survival rates. However, despite a favorable initial response, some cancer cells become resistant and develop into fatal metastatic disease. Here we report that we can specific...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0828-9

    authors: Zhang KX,Kim C,Chow E,Chen IS,Jia W,Rennie PS

    更新日期:2011-01-01 00:00:00

  • Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.

    abstract::The transcriptome of breast cancers have been extensively screened with microarrays and large sets of genes associated with clinical features have been established. The aim of this study was to validate original gene sets on a large cohort of raw breast cancer microarray data with known clinical follow-up. We recovere...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-008-0242-8

    authors: Györffy B,Schäfer R

    更新日期:2009-12-01 00:00:00

  • The clinical value of preoperative wire localization of breast lesions by magnetic resonance imaging--a multicenter study.

    abstract::To evaluate the clinical value of MRI guided preoperative wire localization of clinically and mammographically occult lesions of the breast. In a multicenter study, we evaluated 132 preoperative MRI guided localizations. Median lesion size evaluated by MRI prior to wire localization was 9mm. MRI guided localization wa...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1023/a:1019668210290

    authors: Lampe D,Hefler L,Alberich T,Sittek H,Perlet C,Prat X,Taourel P,Amaya B,Koelbl H,Heywang-Kobrunner SH

    更新日期:2002-09-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract::To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-011-1776-8

    authors: Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期:2012-01-01 00:00:00

  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

    abstract::FOXP3-expressing T regulatory lymphocytes (Tregs) have been described as putative mediators of immune tolerance, and thus facilitators of tumor growth. When found in association with various malignancies, Tregs are generally markers of poor clinical outcome. However, it is unknown whether they are also associated with...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2556-4

    authors: Lal A,Chan L,Devries S,Chin K,Scott GK,Benz CC,Chen YY,Waldman FM,Hwang ES

    更新日期:2013-06-01 00:00:00

  • Psychological impact of recall in high-risk breast MRI screening.

    abstract:PURPOSE:To address the widespread concern that false-positive results during breast MRI screening may have adverse psychological effects. METHODS:Impact of Event Scale measurements in 103 high-risk women enrolled in a longitudinal MRI screening study and comparison of subjects with normal results vs. those with prior ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-008-0140-0

    authors: O'Neill SM,Rubinstein WS,Sener SF,Weissman SM,Newlin AC,West DK,Ecanow DB,Rademaker AW,Edelman RR

    更新日期:2009-05-01 00:00:00

  • Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

    abstract::The prognostic value of proliferative activity and its relationship with steroid hormone receptors and histopathological grade have been demonstrated for breast cancers. However, nothing is known about the underlying mechanisms. In order to understand the chronology of the appearance of increased proliferative activit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01831474

    authors: Remvikos Y,Gerbault-Seureau M,Magdelénat H,Prieur M,Dutrillaux B

    更新日期:1992-01-01 00:00:00

  • Tamoxifen-induced increases in cytoplasmic free Ca2+ levels in human breast cancer cells.

    abstract::Tamoxifen has been shown to increase cytoplasmic free Ca2+ levels [Ca2+]i in renal tubular cells and bladder cancer cells, and to after Ca2+ signaling in MCF-7 breast cancer cells. The present study examined the effect of tamoxifen on [Ca2+], in ZR-75-1 human breast cancer cells using fura-2 as an indicator. Tamoxifen...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1013807731642

    authors: Chang HT,Huang JK,Wang JL,Cheng JS,Lee KC,Lo YK,Liu CP,Chou KJ,Chen WC,Su W,Law YP,Jan CR

    更新日期:2002-01-01 00:00:00

  • Class distribution of immunoglobulin-containing plasma cells in the stroma of medullary carcinoma of breast.

    abstract::A class distribution of plasma cells associated with the stroma in twenty-eight cases of medullary carcinoma of the breast was investigated by an unlabeled immunoperoxidase method. The stroma of the medullary carcinomas tested was found to contain predominantly IgG plasma cells except in two cases. Stroma of the other...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806794

    authors: Ito T,Saga S,Nagayoshi S,Imai M,Aoyama A,Yokoi T,Hoshino M

    更新日期:1986-01-01 00:00:00

  • Hormones and hormone receptors in the etiology of breast cancer.

    abstract::Many epidemiologic features of breast cancer suggest that endogenous hormones are of importance in the genesis of this disease. Endocrinologic studies based on total levels of various hormones in serum and urine have provided etiologic clues, but have failed to yield a clear understanding of the hormonal aberrations t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:

    authors: Thomas DB

    更新日期:1986-01-01 00:00:00

  • Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity.

    abstract::Multiple adjuvant regimens are used for HER2+ breast cancer, but experience in routine practice is not reported. We evaluated whether oncologists' perceptions of these regimens matches clinical experience. We surveyed Wisconsin medical oncologists throughout the state regarding factors impacting selection of TCH (doce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1862-y

    authors: Rocque G,Onitilo A,Engel J,Pettke E,Boshoven A,Kim K,Rishi S,Waack B,Wisinski KB,Tevaarwerk A,Burkard ME

    更新日期:2012-01-01 00:00:00

  • Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.

    abstract::To investigate the prognostic value of tumor markers, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels at diagnosis of systemic recurrence. After primary treatments of locoregional breast cancers, serum CA 15-3 and/or CEA concentrations were regularly measured, and systemic recurrences were iden...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2695-7

    authors: Lee JS,Park S,Park JM,Cho JH,Kim SI,Park BW

    更新日期:2013-10-01 00:00:00

  • Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

    abstract::Tumour hypoxia, being widespread in solid tumours, is related to an increased risk of invasion and metastasis as well as to resistance to chemotherapy and radiotherapy. Hypoxia-inducible factor-1alpha (HIF-1alpha) has emerged as the key regulator of the cellular response to hypoxia. In primary breast cancers, HIF-1alp...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9589-5

    authors: Smollich M,Götte M,Kersting C,Fischgräbe J,Kiesel L,Wülfing P

    更新日期:2008-03-01 00:00:00

  • Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.

    abstract:PURPOSE:For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we analyzed interrater reliability of histopathological DCIS features and assessed their associations with subsequent ipsilateral invasive bre...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05816-x

    authors: Groen EJ,Hudecek J,Mulder L,van Seijen M,Almekinders MM,Alexov S,Kovács A,Ryska A,Varga Z,Andreu Navarro FJ,Bianchi S,Vreuls W,Balslev E,Boot MV,Kulka J,Chmielik E,Barbé E,de Rooij MJ,Vos W,Farkas A,Leeuwis-Fedoro

    更新日期:2020-10-01 00:00:00

  • Influence of age and parity on the development of the human breast.

    abstract::Breast cancer is heavily influenced by the reproductive history of the individual. Pregnancy has a protective effect which is attributed to differences in the degree of differentiation of the breast. The purpose of this work was to determine whether the quantity and the type of parenchymal structures present in the hu...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01833517

    authors: Russo J,Rivera R,Russo IH

    更新日期:1992-01-01 00:00:00

  • Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

    abstract::Conflicting theories of epithelial carcinogenesis disagree on the clonal composition of primary tumors and on the time at which metastases occur. In order to study the spatial distribution of disparate clonal populations within breast carcinomas and the extent of the genetic relationship between primary tumors and reg...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9317-6

    authors: Torres L,Ribeiro FR,Pandis N,Andersen JA,Heim S,Teixeira MR

    更新日期:2007-04-01 00:00:00

  • The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?

    abstract::The goal of the present study was to evaluate the role of the tyrosine kinase receptor fibroblast growth factor-1 (FGFR1) and its ligand, the fibroblast growth factor 2 (FGF2) in determining the response to chemoradiotherapy of breast cancers. S14 was a phase II neoadjuvant study carried out at the Institut Curie that...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2027-3

    authors: Massabeau C,Sigal-Zafrani B,Belin L,Savignoni A,Richardson M,Kirova YM,Cohen-Jonathan-Moyal E,Mégnin-Chanet F,Hall J,Fourquet A

    更新日期:2012-07-01 00:00:00

  • The impact of rehabilitation support services on health-related quality of life for women with breast cancer.

    abstract::As the number of women surviving breast cancer increases, with implications for the health system, research into the physical and psychosocial sequelae of the cancer and its treatment is a priority. This research estimated self-reported health-related quality of life (HRQoL) associated with two rehabilitation interven...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-5151-5

    authors: Gordon LG,Battistutta D,Scuffham P,Tweeddale M,Newman B

    更新日期:2005-10-01 00:00:00

  • Two PALB2 germline mutations found in both BRCA1+ and BRCAx familial breast cancer.

    abstract::Partner and localizer of BRCA2 (PALB2), plays an important functional role in DNA damage repair. Recent studies indicate that germline mutations in PALB2 predispose individuals to a high risk of developing familial breast cancer. Therefore, comprehensive identification of PALB2 germline mutations is potentially import...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3358-7

    authors: Downs B,Kim YC,Xiao F,Snyder C,Chen P,Fleissner EA,Becirovic D,Wen H,Sherman S,Cowan KH,Lynch HT,Wang SM

    更新日期:2015-05-01 00:00:00

  • Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.

    abstract:OBJECTIVES:To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer. METHODS:Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) acco...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4577-x

    authors: Abdel-Rahman O

    更新日期:2018-02-01 00:00:00

  • Follow-up cost of breast cancer patients with localized disease after primary treatment: a randomized trial.

    abstract::We studied the cost of follow-up of 472 breast cancer patients without distant metastasis after primary treatment in four different schedules in a randomized trial. The mean follow-up was 4.2 years. The four schedules differed in frequency of follow-up visits (every third or sixth month) and in intensity of diagnostic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-005-5199-2

    authors: Kokko R,Hakama M,Holli K

    更新日期:2005-10-01 00:00:00

  • Phase II study of amonafide in advanced breast cancer.

    abstract::Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks. Five objective tumour responses of 5.0 month...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01833358

    authors: Scheithauer W,Dittrich C,Kornek G,Haider K,Linkesch W,Gisslinger H,Depisch D

    更新日期:1991-12-01 00:00:00

  • Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families.

    abstract::Although a significant proportion of familial aggregation of breast cancer remains unexplained, many of the currently known breast cancer susceptibility genes, including BRCA1, BRCA2 and TP53, play a role in maintaining genome integrity by engaging in DNA repair. RAD51L1 is one of the five RAD51 paralogs involved in h...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1539-6

    authors: Johnson J,Healey S,Khanna KK,kConFab.,Chenevix-Trench G

    更新日期:2011-08-01 00:00:00